Clinical trial · Interventional
Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer
Diffusion-Weighted MRI for Staging in Localized Prostate Cancer: A Pilot Study
NCT02237612CI-TRIAL-00015582completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This pilot clinical trial studies how well diffusion-weighted magnetic resonance imaging (MRI) works in staging patients with prostate cancer that has not spread to nearby lymph nodes or other parts of the body. New imaging techniques, such as diffusion-weighted MRI, may be a less invasive way of predicting the stage and grade of prostate cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma of the Prostate | Prostate Adenocarcinoma | ALIAS | 0.90 |
| Stage IIA Prostate Cancer | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
| Stage IIB Prostate Cancer | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| diffusion-weighted magnetic resonance imaging | Procedure | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (diffusion-weighted MRI)
- description
- Patients undergo diffusion-weighted MRI of the pelvis.
- interventionNames
- Procedure: diffusion-weighted magnetic resonance imaging
- Other: laboratory biomarker analysis
Primary outcomes (1)
- measure
- Number of patients found to have extracapsular extension and seminal vesicle involvement using Diffusion-Weighted MRI
- timeFrame
- Baseline
- description
- Patients will be imaged using diffusion-weighted MR. Findings will be correlated with histopathologic findings at biopsy and/or prostatectomy.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy-documented adenocarcinoma of the prostate which is intermediate or high risk, defined as possessing one or more of the following features: * Gleason \>= 7 * \> 50% biopsy cores + * Prostate-specific antigen (PSA) \>= 10 * Interested in undergoing a radical prostatectomy as definitive management for prostate cancer * No clinical or radiographic evidence for distant metastatic disease * In subjects with PSA \< 20 no radiographic staging is required in the absence of clinical symptoms for distant metastatic disease; for those with PSA \> 20, a bone scan must document lack of concern for bone involvement Exclusion Criteria: * Ineligible for surgery due to cardiac, pulmonary, or other major comorbidity factor * History of claustrophobia * Pacemaker or other implanted metal objects which would make subject ineligible for MRI, per standard criteria * Unable to give written informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.